3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Unknown
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Lymphoid
1
Head & Neck
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Sarcoma
4
Pancreatic Neoplasms
4
Breast Neoplasms
4
Stomach Neoplasms
3
Squamous Cell Carcinoma of Head and Neck
3
Small Cell Lung Carcinoma
2
Ovarian Neoplasms
2
Neoplasms
2
Gastrointestinal Stromal Tumors
2
Triple Negative Breast Neoplasms
1
Salivary Gland Neoplasms
1
Prostatic Neoplasms
1
Neoplasms, Unknown Primary
1
Neoplasm Metastasis
1
Multiple Myeloma
1
Melanoma
1
Lymphoma, T-Cell, Cutaneous
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Mantle-Cell
1
Lymphoma, Follicular
1
Lymphoma
1
Head and Neck Neoplasms
1
Gallbladder Neoplasms
1
Esthesioneuroblastoma, Olfactory
1
Esophageal Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Hepatocellular
1
Carcinoma, Basal Cell
1
Bile Duct Neoplasms
1
Interventions
pembrolizumab
2
Specimen Handling
2
Nivolumab
2
Magnetic Resonance Spectroscopy
2
tocilizumab
1
poly ICLC
1
flt3 ligand protein
1
daromun
1
SUB1 protein, human
1
Radiotherapy
1
Radiation
1
Mohs Surgery
1
Melphalan
1
Ipilimumab
1
IPI-926
1
Capecitabine
1
CTLA-4 Antigen
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Basal Cell
×
Capecitabine
×
Sarcoma
×
Clear all
NCT03775525
2022-12-23
GEN602
Genzada Pharmaceuticals USA, Inc.
Phase 1
Unknown
127 enrolled